A review of the use of zonisamide in Parkinson-s disease

Therapeutic Advances in Neurological Disorders

Volumn 2, Issue 5, 2009, Pages 313-317

  Bermejo, Pedro Emilio ^a   Anciones, Buenaventura ^a  

^a Sanatorio Nuestra Senora del Rosario Hospital Sanitas La Zarzuela   (Colombia)

Author keywords

antiepileptic; neuromodulator; Parkinson s disease; zonisamide

Indexed keywords

AMPA RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; ETIRACETAM; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; TOPIRAMATE; ZONISAMIDE;

ADD ON THERAPY; ANXIETY; APATHY; BIOAVAILABILITY; CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; HUMAN; IMPULSE CONTROL DISORDER; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION;

EID: 77953374939     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285609338501     Document Type: Review

References (33)

1. Arzimanoglou, A. and Rahbani, A. ( 2006) Zonisamide for the treatment of epilepsy. Expert Rev Neurother 6: 1283-1292.
2. Bazil, C.W. ( 2004) Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr Neurol Neurosci Rep 4: 305-307.
3. Bermejo, P.E. ( 2008) Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 14: 448-449.
4. Bermejo, P.E. ( 2007) Zonisamide in patients with essential tremor and Parkinson's disease. Mov Disord 22: 2137-2138.
5. Bermejo, P.E. and Dorado, R. Zonisamide for migraine prophylaxis in refractory patients to topiramate. Clin Neuropharmacol, in press.
6. Bermejo, P.E., Gomez-Argüelles, J.M. and Sepúlveda, J.M. ( 2008) Role of antiepileptic drugs in Parkinson's disease. Med Clin (Barc) 131: 466-471.
7. Bermejo, P.E., Ruiz-Huete, C., Dorado, R. and Anciones, B. ( 2008) Zonisamide in refractory essential tremor. Rev Neurol 46: 139-142.
8. Bermejo, P.E. and Velasco, R. ( 2008) Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 255(Suppl 2): 167 [Abstract].
9. Bermejo, P.E., Zabala, J.A. and Saez, R. ( 2007) Restless legs syndrome induced by zonisamide. Mov Disord 22: 1517-1518.
10. Biton, V. ( 2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30: 230-240.
11. Carod-Artal, F.J., Ziomkowski, S., Mourao Mesquita, H. and Martínez-Martín, P. (2008) Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism Relat Disord 14: 102-108.
12. Chen, J.T., Garcia, P.A. and Alldredge, B.K. ( 2003) Zonisamide-induced restless legs syndrome. Neurology 60: 147.
13. Friedman, J.H., Brown, R.G., Comella, C., Garber, C.E., Krupp, L.B., Lou, J.S. et al. (2007) Fatigue in Parkinson's disease: a review. Mov Disord 22: 297-308.
14. Gluck, M.R., Santana, L.A., Granson, H. and Yahr, M.D. ( 2004) Novel dopamine releasing response of an anticonvulsant agent with possible anti-Parkinson's activity. J Neural Transm 111: 713-724.
15. Gómez-Esteban, J.C., Zarranz, J.J., Tijero, B., Velasco, F., Barcena, J., Rouco, I. et al. (2007) Restless legs syndrome in Parkinson's disease. Mov Disord 22: 1912-1916.
16. Guay, D.R. ( 2003) Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 1: 18-37.
17. Huang, C.W., Ueno, S., Okada, M. and Kaneko, S. ( 2005) Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res 67: 51-60.
18. Jankovic, J. ( 2006) An update on the treatment of Parkinson's disease. Mt Sinai J Med 73: 682-689.
19. Kajimoto, Y., Nakanishi, I. and Kondo Wakayama, T. ( 2008) One year follow-up study of the zonisamide (ZNS) efficacy on parkinsonism. Mov Disord 23(Suppl 1): 214 [Abstract].
20. Kashihara, K. ( 2006) Weight loss in Parkinson's disease. J Neurol 253: 38-41.
21. Kinrys, G., Vasconcelos e Sa, D. and Nery, F. ( 2007) Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61: 1050-1053.
22. Konitsiotis, S., Blanchet, P.J., Verhagen, L., Lamers, E. and Chase, T.N. ( 2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54: 1589-1595.
23. Kubo, M., Nishikawa, N., Yabe, H., Nagai, M., Moritoyo, H., Moritoyo, T. et al. (2008) Zonisamide increased metabolism of dopamine neurons in MPTP-treated C57BL/6 and common marmosets. Mov Disord 23(Suppl 1): 311 [Abstract].
24. Michael, C.T. and Starr, J.L. ( 2007) Psychosis following initiation of zonisamide. Am J Psychiatry 164: 682.
25. Miwa, H. ( 2007) Zonisamide for the treatment of Parkinson's disease. Expert Rev Neurother 7: 1077-1083.
26. Morita, S., Miwa, H. and Kondo, T. ( 2005) Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 11: 101-103.
27. Murata, M., Hasegawa, K. and Kanazawa, I. ( 2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68: 45-50.
28. Murata, M., Horiuchi, E. and Kanazawa, I. ( 2001) Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 41: 397-399.
29. Nakanishi, I., Kohmoto, J., Miwa, H. and Kondo, T. ( 2003) Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei 55: 685-689.
30. Ondo, W.G. ( 2007) Zonisamide for essential tremor. Clin Neuropharmacol 30: 345-349.
31. Wichmann, T. and de Long, M.R. ( 2006) Basal ganglia discharge abnormalities in Parkinson's disease. J Neural Transm 70: 21-25.
32. Willmore, L.J. ( 2005) Antiepileptic drugs and neuro-protection: current status and future roles. Epilepsy Behav 7(Suppl. 3): 25-28.
33. Zesiewicz, T.A., Ward, C.L., Hauser, R.A., Sanchez-Ramos, J., Staffetti, J.F. and Sullivan, K.L. ( 2007) A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 22: 279-282.